NMD could degrade TP53 mutants with nonsense mutation downstream of exon 9 according to 50–55nt rules [11], thus the strategy of combining NMD and MDM2 inhibition could achieve synergistic effects in the subgroup of cancers with TP53 mutation. The gene discussed is TP53; the disease is cancer.